Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Prognostic biomarkers for the response to the radiosensitizer nimorazole combined with RCTx: a pre-clinical trial in HNSCC xenografts

Fig. 1

Experimental setup: For local tumor control we investigated radiochemotherapy (RCTx) plus weekly cislatin (cis) with and without nimorazole (nimo) using the following three treatment arms: RCTx + nimorazole after 10 fractions (fx), RCTx + nimorazole and RCTx + carrier. For histological evaluation and RNA-profiling we investigated RCTx + carrier and RCTx + nimorazole treatment after 10fx as well as untreated tumors. Abbreviations in graphic: nimo: nimorazole, cis: cisplatin

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us